REGN logo

REGN Regeneron Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$923.34
-22.19 (-2.35%)

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovas…

Market Cap: $95.50Bwww.regeneron.com

Price

$803.48+41.52%
$542.52$632.44$722.35$812.27
Jul 2025Aug 2026

Social Signal Score

51
5d
53
8 mentions
+0.0%
30d
52
35 mentions
+0.0%
60d
49
61 mentions
+0.0%
90d
51
76 mentions
+0.0%
rss: 22 · news: 48 · marketaux: 5 · podcast: 1

Analyst Ratings

49 analysts
Buyconsensus
Strong Buy 0Buy 34Hold 15Sell 0Strong Sell 0
Avg price target$925.53+0.2%
Low $756Median $920High $1,100
Current Consensus

52-week range

$555.51$812.27
Last close
$803.48
Off 52w high
-1.1%
200-day average
$720.14
vs 200-day
+11.6%

Revenue

$5.12B+316.99%
$1.23B$2.53B$3.83B$5.14B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$43.48
$42.27–$45.32
17 analysts
FY2026
$68.23+57% YoY
$54.98–$75.39
15 analysts
FY2027
$70.90+4% YoY
$60.66–$78.21
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Leonard S. Schleifer
Sector
Healthcare
Industry
Biotechnology
Employees
15,410
Beta
0.24
Country
US
Piotroski score
7 / 9 (Strong)
Altman Z-score
7.81
www.regeneron.com